Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma

被引:41
作者
Chan, Stephen Lam [1 ]
Wong, Lin-Lee [2 ,3 ]
Chan, Kwan-Chee Allen [4 ]
Chow, Chit [5 ]
Tong, Joanna Hung-Man [5 ]
Yip, Terry Cheuk-Fung [6 ]
Wong, Grace Lai-Hung [6 ]
Chong, Charing Ching-Ning [7 ]
Liu, Po-Hong [8 ,9 ]
Chu, Cheuk-Man [10 ]
Wong, Vincent Wai-Sun [6 ]
To, Ka-Fai [5 ]
Reeves, Helen L. [3 ,11 ]
Chan, Anthony Wing-Hung [5 ]
机构
[1] Chinese Univ Hong Kong, Inst Digest Dis, Sir YK Pao Ctr Canc, Lab Translat Oncol,Dept Clin Oncol, Hong Kong, Peoples R China
[2] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England
[3] Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Hosp, Liver Unit, Newcastle Upon Tyne, Tyne & Wear, England
[4] Chinese Univ Hong Kong, Prince Wales Hosp, Lab Translat Oncol, Dept Chem Pathol, Hong Kong, Peoples R China
[5] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Lab Translat Oncol, Hong Kong, Peoples R China
[6] Chinese Univ Hong Kong, State Key Lab Digest Dis, Inst Digest Dis, Dept Med & Therapeut, Hong Kong, Peoples R China
[7] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Peoples R China
[8] UT Southwestern Med Ctr, Dept Med, Dallas, TX USA
[9] Natl Yang Ming Univ, Sch Med, Fac Med, Taipei, Taiwan
[10] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Imaging & Intervent Radiol, Hong Kong, Peoples R China
[11] Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England
基金
英国医学研究理事会;
关键词
Inflammation; Liver cancer; Prognosis; Tumor markers; NEUTROPHIL-LYMPHOCYTE RATIO; PROGNOSTIC INDEX; SCORE; SURVIVAL; SYSTEM; CANCER; RESECTION; ALBI; APPLICABILITY; VALIDATION;
D O I
10.1159/000504252
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The aim of current study was to (1) construct and validate a novel hepatocellular carcinoma (HCC)-specific inflammatory index; (2) compare the performances of the Integrated Liver Inflammatory Score (ILIS) to existing 4 inflammatory indices in HCC; (3) explore the association between the inflammatory indices and systemic/intratumoral inflammatory markers. Methods: Two cohorts from Hong Kong (HK; n = 1,315) and Newcastle (n = 574) were studied. A novel index was constructed from the HK training set (n = 627). The index was constructed from the training set by combing independent prognostic circulating parameters, followed by validating in the validation set of HK cohort (n = 688) and the Newcastle cohort. Its prognostic performance was compared to 4 inflammatory indices, namely, the neutrophil to lymphocyte ratio, platelet-to-lymphocyte ratio, prognostic nutrition index, and systemic immune-inflammation index, were compared in the HK cohort. Circulating cytokines and intratumoral gene expression were analyzed in a subset of patients with available samples and correlated with the inflammatory indices. Results: In the training set of the HK cohort, the ILIS, was generated: -0.057 x albumin (g/L) + 0.978 x log (Bilirubin, mu mol/L) + 1.341 x log (alkaline phosphatase, IU/L) + 0.086 x Neutrophil (10(9)/L) + 0.301 x log (alpha-fetoprotein, mu g/L). With cutoff of 2.60 and 3.87, the ILIS could categorize patients into 3 risk groups in the both validation cohorts. ILIS outperforms other inflammatory indices and remains an independent prognosticator for overall survival after adjustment with Barcelona Clinic Liver Cancer (hazard ratio 31.90, p < 0.001). The ILIS had the best prognostic performances as compared to other inflammatory indices. In exploratory analyses, the ILIS correlated with circulating inflammatory cytokines (e.g., IL-8) but not with any intratumoral inflammatory gene expression. Conclusions: ILIS is an HCC-specific prognostic index built on 5 readily available blood parameters. Its versatility is validated both Eastern and Western population of HCC. The score is correlated with levels of circulating cytokines.
引用
收藏
页码:167 / 181
页数:15
相关论文
共 41 条
  • [1] Automated variable selection methods for logistic regression produced unstable models for predicting acute myocardial infarction mortality
    Austin, PC
    Tu, JV
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2004, 57 (11) : 1138 - 1146
  • [2] Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
    Bagley, Stephen J.
    Kothari, Shawn
    Aggarwal, Charu
    Bauml, Joshua M.
    Alley, Evan W.
    Evans, Tracey L.
    Kosteva, John A.
    Ciunci, Christine A.
    Gabriel, Peter E.
    Thompson, Jeffrey C.
    Stonehouse-Lee, Susan
    Sherry, Victoria E.
    Gilbert, Elizabeth
    Eaby-Sandy, Beth
    Mutale, Faith
    DiLullo, Gloria
    Cohen, Roger B.
    Vachani, Anil
    Langer, Corey J.
    [J]. LUNG CANCER, 2017, 106 : 1 - 7
  • [3] Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients
    Berhane, Sarah
    Toyoda, Hidenori
    Tada, Toshifumi
    Kumada, Takashi
    Kagebayashi, Chiaki
    Satomura, Shinji
    Schweitzer, Nora
    Vogel, Arndt
    Manns, Michael P.
    Benckert, Julia
    Berg, Thomas
    Ebker, Maria
    Best, Jan
    Dechene, Alexander
    Gerken, Guido
    Schlaak, Joerg F.
    Weinmann, Arndt
    Worns, Marcus A.
    Galle, Peter
    Yeo, Winnie
    Mo, Frankie
    Chan, Stephen L.
    Reeves, Helen
    Cox, Trevor
    Johnson, Philip
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (06) : 875 - +
  • [4] Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
    Bruix, Jordi
    Cheng, Ann-Lii
    Meinhardt, Gerold
    Nakajima, Keiko
    De Sanctis, Yoriko
    Llovet, Josep
    [J]. JOURNAL OF HEPATOLOGY, 2017, 67 (05) : 999 - 1008
  • [5] nCounter® PanCancer Immune Profiling Panel (NanoString Technologies, Inc., Seattle, WA)
    Cesano, Alessandra
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2015, 3
  • [6] Incorporating albumin-bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma
    Chan, Anthony W. H.
    Chong, Charing C. N.
    Mo, Frankie K. F.
    Wong, John
    Yeo, Winnie
    Johnson, Philip J.
    Yu, Shuangni
    Lai, Paul B. S.
    Chan, Anthony T. C.
    To, Ka-Fai
    Chan, Stephen L.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 (01) : 221 - 228
  • [7] Applicability of albumin-bilirubin-based Japan integrated staging score in hepatitis B-associated hepatocellular carcinoma
    Chan, Anthony W. H.
    Chong, Charing C. N.
    Mo, Frankie K. F.
    Wong, John
    Yeo, Winnie
    Johnson, Philip J.
    Yu, Shuangni
    Lai, Paul B. S.
    Chan, Anthony T. C.
    To, Ka-Fai
    Chan, Stephen L.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 (10) : 1766 - 1772
  • [8] Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma
    Chan, Anthony W. H.
    Kumada, Takshi
    Toyoda, Hidenori
    Tada, Toshifumi
    Chong, Charing C. N.
    Mo, Frankie K. F.
    Yeo, Winnie
    Johnson, Philip J.
    Lai, Paul B. S.
    Chan, Anthony T. C.
    To, Ka-Fai
    Chan, Stephen L.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 (07) : 1300 - 1306
  • [9] Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection
    Chan, Anthony W. H.
    Chan, Stephen L.
    Wong, Grace L. H.
    Wong, Vincent W. S.
    Chong, Charing C. N.
    Lai, Paul B. S.
    Chan, Henry L. Y.
    To, Ka-Fai
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (13) : 4138 - 4148
  • [10] Albumin-to-Alkaline Phosphatase Ratio: A Novel Prognostic Index for Hepatocellular Carcinoma
    Chan, Anthony W. H.
    Chan, Stephen L.
    Mo, Frankie K. F.
    Wong, Grace L. H.
    Wong, Vincent W. S.
    Cheung, Yue-Sun
    Chan, Henry L. Y.
    Yeo, Winnie
    Lai, Paul B. S.
    To, Ka-Fai
    [J]. DISEASE MARKERS, 2015, 2015 : 1 - 10